|
    CTIC U.S.: Nasdaq

    CTI BioPharma Corp.

    CTICUS
    Open
    Back To Top
    Last Updated: Jun 23, 2021 10:57 a.m. EDT Real time quote

    $ 2.3200

    0.0300 1.31%
    Previous Close
    $2.2900
    Advanced Charting
    • $
    • %
    • Vol
    Volume: 165.33K 65 Day Avg: 1.03M
    16% vs Avg
    2.2900 Day Range 2.3200
    0.9629 52 Week Range 4.1300

    Your Watchlists

    Customize eLesor

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    CTIC Overview

    Performance

    5 Day
    • -2.93%
    1 Month
    • -0.85%
    3 Month
    • -17.73%
    YTD
    • -27.95%
    1 Year
    • 91.74%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 5 Full Ratings

    Recent News

    • eLesor
    • Dow Jones

    CTI BioPharma Gets FDA Priority Review of Pacritinib >CTIC

    CTI BioPharma started at buy with $5.50 stock price target at Stifel Nicolaus

    UPDATE: CTI BioPharma stock slides 12% after failed trial of treatment for non-Hodgkin lymphoma

    CTI BioPharma shares slide 37% after resuming trade following halt

    CTI BioPharma shares halted premarket for the news

    CTI BioPharma says tria of treatment for non-Hodgkin lymphoma did not meet main goals

    CTI BioPharma initiated with outperform rating at Oppenheimer

    Read full story

    Two charts that tell investors we won’t get a stock meltdown, but brace anyway

    Read full story

    Use the January Effect for a potential 30% return

    Read full story

    Investors in health-care stocks get rich as M&A booms

    Read full story

    Friday’s biggest gaining and declining stocks

    Cell Therapeutics down 21% in premarket

    Read full story

    Tuesday’s biggest gaining and declining stocks

    Cell Therapeutics up 21% in premarket

    CTIC gets orphan drug status for brain cancer drug

    Cell Therapeutics: progress with lymphoma Drug

    Read full story

    Tuesday’s top gaining and declining stocks

    Cell Therapeutics soars 24% on EU drug launch

    Read full story

    Tuesday’s biggest gaining and declining stocks

    Updates, advisories and surprises

    • Other News
    • Press Releases

    7 Reddit Penny Stocks to Buy if You Have $100 to Spare

    on InvestorPlace.com

    CTI BioPharma (CTIC) Receives a Buy from Needham

    on SmarterAnalyst

    CTI BioPharma (CTIC) Q1 2021 Earnings Call Transcript

    on Motley Fool

    7 Reddit Penny Stocks Promising to Cure Cancer

    on InvestorPlace.com

    7 Penny Stocks That May Not Be Penny Stocks For Long

    on InvestorPlace.com

    Analysts Offer Insights on Healthcare Companies: CTI BioPharma (CTIC), Pfizer (PFE) and Flexion Therapeutics (FLXN)

    on SmarterAnalyst

    Analysts Offer Insights on Healthcare Companies: CTI BioPharma (CTIC) and TCR2 Therapeutics (TCRR)

    on SmarterAnalyst

    Analysts Are Bullish on Top Healthcare Stocks: CTI BioPharma (CTIC), Apellis Pharmaceuticals (APLS)

    on SmarterAnalyst

    CTI BioPharma (CTIC) Receives a Buy from Needham

    on SmarterAnalyst

    Brookline Capital Markets Sticks to Their Buy Rating for CTI BioPharma (CTIC)

    on SmarterAnalyst

    CTI BioPharma (CTIC) Q4 2020 Earnings Call Transcript

    on Motley Fool

    CTI BioPharma (CTIC) Receives a Buy from Brookline Capital Markets

    on SmarterAnalyst

    CTI BioPharma (CTIC) Gets a Buy Rating from Needham

    on SmarterAnalyst

    Brookline Capital Markets Believes CTI BioPharma (CTIC) Still Has Room to Grow

    on SmarterAnalyst

    Needham Releases a Buy Rating on CTI BioPharma (CTIC)

    on SmarterAnalyst

    CTI BioPharma Corp.

    CTI BioPharma Corp. is a biopharmaceutical company, which focuses on the development, acquisition and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

    Competitors

    Name Chg % Market Cap
    Eli Lilly & Co. -1.46% $212.37B
    Madrigal Pharmaceuticals Inc. -0.51% $1.7B
    Bristol Myers Squibb Co. -0.85% $147.31B
    Novartis AG ADR -0.50% $210.32B
    Incyte Corp. -0.48% $18.71B
    Teva Pharmaceutical Industries Ltd. ADR 0.25% $11.3B
    Baxter International Inc. 0.22% $40.9B
    Amgen Inc. -0.55% $137.84B
    Competitor Data Provided ByCapital Cube Logo